STX101 and STX105, our lead Syntides, are stabilized peptide therapeutics that inhibit an interaction essential in the Homologous Recombination (HR) DNA repair pathway.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

​

We are developing STX101 and STX105 as monotherapy candidates for specific types of cancers which are dependent on HR for chemo evasion. We are specificially pursing STX100 compounds for efficacy towards intrahepatic cholangiocarcinomas (ICC) and castration-resistant prostate cancer (mCRPC).

​

These syntides are also being developed for combination therapy with current chemotherapy drugs, enabling a lower dosing, increased efficacy and reduced side effects.

Due to the targeting of HR, our compounds also hold particular promise for the treatment of children with Bloom’s syndrome.
STX100 series
C

STX201 pancreatic cancer
STX301 KRAS-driven cancers